Stem Cells
Therapies
Stem Cells Therapies
The purpose of banking stem cells is to apply them in the therapy. For the first time cord blood was used in 1988 and since then according to publicly available statistics it has been used over 85 000 times worldwide (including statistics of China).
FamiCord Group stores over 1,000,000 samples of cells of different types and has supplied stem cells for application in clinic for more than 7000 patients. We supply stem cells for standard transplantations (cord blood , bone marrow and mobilized peripheral blood) and cellular therapies. On top of that we provide cell based products in GMP standard for clinical trials.
Stem cells manufactured in our premises helped patients with various diseases and therapeutic areas, including haematological, neurological, ophthalmological, orthopaedical, dermatological disorders.
Check the full list of patients who received stem cell therapy derived from FamiCord labs.
List last update: 06.2026
List of patients who received stem cells from FamiCord Group laboratories
| Lp. | Source | Source type | Diagnosis | Medical field | Year of application | Therapy | Country | Age of recipient |
|---|---|---|---|---|---|---|---|---|
| 1201 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Australia | 71 |
| 1202 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 76 |
| 1203 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Canada | 66 |
| 1204 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 74 |
| 1205 | Apheresis | Allogeneic | Morbus Hodgkin | Hematology | 2025 | Standard Therapy | Germany | 21 |
| 1206 | Apheresis | Allogeneic | Myelodysplastic Disorders | Hematology | 2025 | Standard Therapy | France | 66 |
| 1207 | Apheresis | Allogeneic | Mielodysplastic Syndrome | Hematology | 2025 | Standard Therapy | USA | 65 |
| 1208 | Apheresis | Allogeneic | T Lymphoblastic Lymphoma | Hematology | 2025 | Standard Therapy | Portugal | 25 |
| 1209 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Romania | 29 |
| 1210 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | France | 37 |
| 1211 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 49 |
| 1212 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 32 |
| 1213 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 72 |
| 1214 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 43 |
| 1215 | Apheresis | Allogeneic | Hodking lymphoma | Hematology | 2025 | Standard Therapy | Serbia | 32 |
| 1216 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Canada | 66 |
| 1217 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 71 |
| 1218 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 66 |
| 1219 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 68 |
| 1220 | Apheresis | Allogeneic | OMDS/ Myeloproliferative Neoplasie | Hematology | 2025 | Standard Therapy | Switzerland | 46 |
| 1221 | Apheresis | Allogeneic | Myelofibrosis Myeloid Metaplasia | Hematology | 2025 | Standard Therapy | USA | 3 |
| 1222 | Apheresis | Allogeneic | Myelofibrosis Myeloid Metaplasia | Hematology | 2025 | Standard Therapy | USA | 75 |
| 1223 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | USA | 58 |
| 1224 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Greece | 63 |
| 1225 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | USA | 64 |
| 1226 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Germany | 65 |
| 1227 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Spain | 49 |
| 1228 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Poland | 30 |
| 1229 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 66 |
| 1230 | Apheresis | Allogeneic | Chronic Lymphocyte Leukemia | Hematology | 2025 | Standard Therapy | Canada | 55 |
| 1231 | Apheresis | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 64 |
| 1232 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Poland | 16 |
| 1233 | Apheresis | Allogeneic | Chronic Myelomonocytic Leukemia | Hematology | 2025 | Standard Therapy | USA | 73 |
| 1234 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Ukraine | 47 |
| 1235 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | USA | 64 |
| 1236 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | France | 67 |
| 1237 | Apheresis | Allogeneic | Other Myelofibrosis/Myelosclerosis | Hematology | 2025 | Standard Therapy | USA | 65 |
| 1238 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Germany | 58 |
| 1239 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2025 | Standard Therapy | Germany | 57 |
| 1240 | Apheresis | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | RUSSIAN FEDERATION | 22 |
| 1241 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Ukraine | 33 |
| 1242 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Slovakia | 41 |
| 1243 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Greece | 54 |
| 1244 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Ukraine | 46 |
| 1245 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Argentina | 26 |
| 1246 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | USA | 70 |
| 1247 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 59 |
| 1248 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 34 |
| 1249 | Apheresis | Allogeneic | Myelofibrosis | Hematology | 2025 | Standard Therapy | Norway | 53 |
| 1250 | Apheresis | Allogeneic | Other Immune System | Hematology | 2025 | Standard Therapy | USA | 19 |
| 1251 | Apheresis | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | Poland | 6 |
| 1252 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | USA | 68 |
| 1253 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 72 |
| 1254 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Germany | 64 |
| 1255 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | United Kingdom | 33 |
| 1256 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Italy | 63 |
| 1257 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Lithuania | 33 |
| 1258 | Apheresis | Autologous | Central Nervous System Lymphoma | Hematology | 2025 | Standard Therapy | Germany | 61 |
| 1259 | Apheresis | Allogeneic | Acute lymphocytic leukemia | Hematology | 2025 | Standard Therapy | Germany | 51 |
| 1260 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 64 |
| 1261 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 54 |
| 1262 | Apheresis | Autologous | Testicular tumor | Hematology | 2025 | Standard Therapy | Germany | 42 |
| 1263 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 52 |
| 1264 | Apheresis | Autologous | T-cell lymphoma | Hematology | 2025 | Standard Therapy | Germany | 49 |
| 1265 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 73 |
| 1266 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 62 |
| 1267 | Apheresis | Autologous | Lymphoma Hodgkin | Hematology | 2025 | Standard Therapy | Portugal | 39 |
| 1268 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2025 | Standard Therapy | Germany | 60 |
| 1269 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2025 | Standard Therapy | Germany | 70 |
| 1270 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2025 | Standard Therapy | Germany | 64 |
| 1271 | Apheresis | Autologous | T-Cell Lymphoma | Hematology | 2025 | Standard Therapy | Germany | 60 |
| 1272 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2025 | Standard Therapy | Germany | 62 |
| 1273 | Apheresis | Autologous | Mantle Cell Lymphoma | Hematology | 2025 | Standard Therapy | Germany | 60 |
| 1274 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2025 | Standard Therapy | Germany | 43 |
| 1275 | Apheresis | Allogeneic | Myeofibrosis | Hematology | 2025 | Standard Therapy | Poland | 37 |
| 1276 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Russia | 22 |
| 1277 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | NETHERLANDS | 66 |
| 1278 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | France | 57 |
| 1279 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | United Kingdom | 56 |
| 1280 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 78 |
| 1281 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | USA | 65 |
| 1282 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 53 |
| 1283 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Portugal | 41 |
| 1284 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | United Kingdom | 56 |
| 1285 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 22 |
| 1286 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Poland | 36 |
| 1287 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Canada | 65 |
| 1288 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 71 |
| 1289 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Sweden | 73 |
| 1290 | Apheresis | Allogeneic | NK LGL Leukemia | Hematology | 2025 | Standard Therapy | USA | 42 |
| 1291 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Italy | 29 |
| 1292 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 71 |
| 1293 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 68 |
| 1294 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Czechia | 64 |
| 1295 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 10 |
| 1296 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Brazil | 57 |
| 1297 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Lithuania | 21 |
| 1298 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Lithuania | 54 |
| 1299 | Apheresis | Allogeneic | Richter Transformation From CLL | Hematology | 2025 | Standard Therapy | Poland | 55 |
| 1300 | Apheresis | Allogeneic | Richter Transformation From CLL | Hematology | 2025 | Standard Therapy | Poland | 63 |